Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation (Study MK-4448-006)

This study has been completed.
Portola Pharmaceuticals
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: September 9, 2010
Last updated: November 6, 2014
Last verified: November 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2011
  Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)